Inicio
Detalle del título uniforme
Alzheimer's Research & Therapy
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (1)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study / Martín Ochoa Escudero ; Sergio Álvarez Vallejo
Título : Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study Tipo de documento : documento electrónico Autores : Martín Ochoa Escudero, ; Sergio Álvarez Vallejo, Fecha de publicación : 2021 Títulos uniformes : Alzheimer's Research & Therapy Idioma : Inglés (eng) Palabras clave : Alzheimer’s Amyloid Autosomal-Dominant Imaging Longitudinal Tau Resumen : Background: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset. Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD. Methods: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of Aβ (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period. Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers. Results: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with Aβ accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO). Rates of tau accumulation among carriers were most rapid in parietal neocortex (~ 9%/year). EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers. Conclusions: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between Aβ burden and neocortical tau accumulation in ADAD. Mención de responsabilidad : Justin S. Sanchez, Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Ana Baena, Yamile Bocanegra, David Aguillon, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, Liliana Ramirez-Gomez, Clara Vila-Castelar, Jairo E. Martinez, Joshua T. Fox-Fuller, Claudia Ramos, Martin Ochoa-Escudero, Sergio Alvarez, Heidi I. L. Jacobs, Aaron P. Schultz, Jennifer R. Gatchel, J. Alex Becker, Samantha R. Katz, Danielle V. Mayblyum, Julie C. Price, Eric M. Reiman, Keith A. Johnson and Yakeel T. Quiroz Referencia : Alzheimers Res Ther. 2021 Jan 15;13(1):27. DOI (Digital Object Identifier) : 10.1186/s13195-020-00765-5 PMID : 33451357 Derechos de uso : CC BY En línea : https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00765-5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5784 Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study [documento electrónico] / Martín Ochoa Escudero, ; Sergio Álvarez Vallejo, . - 2021.
Obra : Alzheimer's Research & Therapy
Idioma : Inglés (eng)
Palabras clave : Alzheimer’s Amyloid Autosomal-Dominant Imaging Longitudinal Tau Resumen : Background: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset. Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD. Methods: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of Aβ (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period. Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers. Results: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with Aβ accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO). Rates of tau accumulation among carriers were most rapid in parietal neocortex (~ 9%/year). EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers. Conclusions: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between Aβ burden and neocortical tau accumulation in ADAD. Mención de responsabilidad : Justin S. Sanchez, Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Ana Baena, Yamile Bocanegra, David Aguillon, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, Liliana Ramirez-Gomez, Clara Vila-Castelar, Jairo E. Martinez, Joshua T. Fox-Fuller, Claudia Ramos, Martin Ochoa-Escudero, Sergio Alvarez, Heidi I. L. Jacobs, Aaron P. Schultz, Jennifer R. Gatchel, J. Alex Becker, Samantha R. Katz, Danielle V. Mayblyum, Julie C. Price, Eric M. Reiman, Keith A. Johnson and Yakeel T. Quiroz Referencia : Alzheimers Res Ther. 2021 Jan 15;13(1):27. DOI (Digital Object Identifier) : 10.1186/s13195-020-00765-5 PMID : 33451357 Derechos de uso : CC BY En línea : https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00765-5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5784 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001711 AC-2021-034 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2021-034Adobe Acrobat PDF